NCT07208266

Brief Summary

A scientific study to design and implement a contingency management (CM) program, and to evaluate its effectiveness in promoting abstinence and treatment adherence among individuals with opioid use disorder, as well as to explore its potential for broader implementation in clinical settings.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
9mo left

Started Dec 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
Dec 2025Feb 2027

First Submitted

Initial submission to the registry

September 18, 2025

Completed
18 days until next milestone

First Posted

Study publicly available on registry

October 6, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

October 6, 2025

Status Verified

September 1, 2025

Enrollment Period

1 year

First QC Date

September 18, 2025

Last Update Submit

September 27, 2025

Conditions

Keywords

Opioid Use DisorderContingency ManagementAssiut University Hospital

Outcome Measures

Primary Outcomes (2)

  • Relapse Risk Assessment: Assessed using the Advance Warning of Relapse (AWARE) Questionnaire administered at program entry and exit. Changes in AWARE scores will indicate changes in relapse risk and warning signs.

    From baseline (admission) until discharge (~2 weeks), and at 3 months post-discharge

  • Proportion of opioid-negative urine drug screens during inpatient stay and at 3-month follow-up

    From baseline (admission) until discharge (~2 weeks), and at 3 months post-discharge

Study Arms (1)

Contingency Management Intervention

EXPERIMENTAL
Behavioral: contingency management

Interventions

Participants with opioid use disorder admitted to the inpatient addiction management unit will receive a contingency management (CM) program as a behavioral intervention. The program consists of providing positive reinforcement (small rewards or incentives) contingent upon objective evidence of desired behaviors, primarily drug abstinence verified by urine toxicology screening. The intervention will be delivered throughout the inpatient stay (approximately two weeks). Participants' adherence and abstinence will be monitored, and rewards will be adjusted based on performance.

Contingency Management Intervention

Eligibility Criteria

Age18 Years - 75 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Be 18 years of age or older
  • Have a diagnosis of a substance use disorder (SUD) according to DSM-5 criteria
  • Be able to understand and provide informed consent
  • Be willing to comply with study procedures, including regular drug screening and attendance tracking
  • Must be able to swallow tablets

You may not qualify if:

  • Have a severe cognitive impairment or active psychosis that interferes with participation
  • Currently experiencing a medical condition that would make participation unsafe

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (10)

  • Rawson RA, Erath TG, Chalk M, Clark HW, McDaid C, Wattenberg SA, Roll JM, McDonell MG, Parent S, Freese TE. Contingency Management for Stimulant Use Disorder: Progress, Challenges, and Recommendations. J Ambul Care Manage. 2023 Apr-Jun 01;46(2):152-159. doi: 10.1097/JAC.0000000000000450. Epub 2023 Feb 3.

    PMID: 36745163BACKGROUND
  • Kwon M, Yang S, Park K, Kim DJ. Factors that affect substance users' suicidal behavior: a view from the Addiction Severity Index in Korea. Ann Gen Psychiatry. 2013 Nov 12;12(1):35. doi: 10.1186/1744-859X-12-35.

    PMID: 24220264BACKGROUND
  • Petry NM, Barry D, Alessi SM, Rounsaville BJ, Carroll KM. A randomized trial adapting contingency management targets based on initial abstinence status of cocaine-dependent patients. J Consult Clin Psychol. 2012 Apr;80(2):276-85. doi: 10.1037/a0026883. Epub 2012 Jan 9.

    PMID: 22229758BACKGROUND
  • Coughlin LN, Zhang L, Frost MC, Khazanov G, McKay JR, DePhilippis D, Lin LA. Contingency management for substance use disorders in the U.S. Veterans Health Administration: 2018-2022. J Subst Use Addict Treat. 2024 Aug;163:209400. doi: 10.1016/j.josat.2024.209400. Epub 2024 May 11.

    PMID: 38735480BACKGROUND
  • McDonell MG, Skalisky J, Burduli E, Foote A Sr, Granbois A, Smoker K, Hirchak K, Herron J, Ries RK, Echo-Hawk A, Barbosa-Leiker C, Buchwald D, Roll J, McPherson SM. The rewarding recovery study: a randomized controlled trial of incentives for alcohol and drug abstinence with a rural American Indian community. Addiction. 2021 Jun;116(6):1569-1579. doi: 10.1111/add.15349. Epub 2021 Jan 14.

    PMID: 33220122BACKGROUND
  • Petry NM, Tedford J, Austin M, Nich C, Carroll KM, Rounsaville BJ. Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? Addiction. 2004 Mar;99(3):349-60. doi: 10.1111/j.1360-0443.2003.00642.x.

    PMID: 14982548BACKGROUND
  • Dennis M, Scott CK. Managing addiction as a chronic condition. Addict Sci Clin Pract. 2007 Dec;4(1):45-55. doi: 10.1151/ascp074145.

    PMID: 18292710BACKGROUND
  • Sussman S, Sussman AN. Considering the definition of addiction. Int J Environ Res Public Health. 2011 Oct;8(10):4025-38. doi: 10.3390/ijerph8104025. Epub 2011 Oct 20.

    PMID: 22073026BACKGROUND
  • Hofer D, Wenger F, Kohler M, Badertscher M. [Addiction in psychiatric ambulatory service]. Ther Umsch. 2014 Oct;71(10):609-16. doi: 10.1024/0040-5930/a000600. German.

    PMID: 25257115BACKGROUND
  • GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018 Dec;5(12):987-1012. doi: 10.1016/S2215-0366(18)30337-7. Epub 2018 Nov 1.

    PMID: 30392731BACKGROUND

Related Links

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Central Study Contacts

Ragaei Raouf Zaki, Master's degree (M.Sc.) in

CONTACT

Alaa El-Din Mohamed Darwish, Prof

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

September 18, 2025

First Posted

October 6, 2025

Study Start

December 1, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

February 1, 2027

Last Updated

October 6, 2025

Record last verified: 2025-09